A Phase 2 interventional study of Eltrombopag (EPAG) in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia, sponsored by Abhay Singh, MD MPH. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Abhay Singh, MD MPH · Phase 2, Interventional, and Treatment
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing eltrombopag in Myelodysplastic Syndromes — 1 open to participants now, 3 under way, none of them phase 3. eltrombopag · Myelodysplastic Syndromes.
Among the 13 studies testing eltrombopag in Myelodysplastic Syndromes, this one is the 9th largest by planned enrollment, is the only one that started in 2025, is one of 8 in phase 2, and was the 13th registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 318 are open to participants now.
Browse Myelodysplastic Syndromes studies →1 of the 13 studies testing eltrombopag in Myelodysplastic Syndromes is open now, in 1 country.
By country, each count listing its studies:
eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 259 Myelodysplastic Syndromes studies recruiting now, 166 (64%) set no upper age limit and 67 (26%) stop at 75 or younger; 55 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 30 across the 13 interventional studies. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 13 have an industry lead sponsor. The 9 most frequent:
This is the only study on the registry with Abhay Singh, MD MPH as lead sponsor.
Abhay Singh, MD MPH has 1 study filed under Myelodysplastic Syndromes — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing eltrombopag in Myelodysplastic Syndromes, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate if a study drug called eltrombopag can improve the blood cell counts in patients with low-risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) with mutations in TET2 gene, observe changes in the TET2 gene over time, and evaluate the effectiveness of the treatment. TET2 gene is one of the most frequently mutated genes (altered parts of the DNA) in MDS and CMML.
Eltrombopag is a Food and Drug Administration (FDA) approved drug for the treatment of severe aplastic anemia and low levels of platelets in patients with persistent or chronic immune thrombocytopenia (ITP) and chronic hepatitis C. Eltrombopag is considered investigational (experimental) in this study because the FDA has not approved its use in the treatment of low-risk MDS or CMML. Eltrombopag is a drug that helps stimulate the body's process of making more platelets (small components of blood that help with clotting) by interacting with specific parts of cells. This interaction starts a series of signals that encourage the growth and development of the cells that produce platelets. It was found that this drug could stop the growth of TET2 mutated cells.
Epigenetic changes such as alterations in DNA methylation and histone modification play an important role in the pathophysiology of myelodysplastic syndromes (MDS). With the development of next-generation sequencing (NGS) platforms, it has become possible to identify genomic aberrations involved in the MDS epigenetics. Additionally, with the advances in therapeutic methods in MDS, several novel genomic aberrations have been reported to predict the effectiveness of specific treatment. It is becoming clear that genomic aberrations may offer more precise cancer phenotypes and help predict precise therapies for MDS patients (e.g. IDH1 and IDH2 inhibitors). TET2 gene is a member of the DNA methylation machinery and one of the most frequently mutated genes in MDS and chronic myelomonocytic leukemia (CMML; a disease entity similar to MDS with similar bone marrow dysplasia and accompanying cytopenias). TET DNA dioxygenases hydroxylate 5-methylcytosine (5mC) to 5-hydroxy-mC (5hmC), a process that leads to passive demethylation and thereby initiation of differentiation programs of hematopoietic stem cells (HSCs). TET2 mutations (TET2MT) often act as founder lesions for clonal hematopoiesis of indeterminate potential (CHIP). Our group has demonstrated that mutational exclusivity of TET2 and isocitrate dehydrogenases 1 and 2 (IDH1/2) result from production of a neomorphic natural TET2 inhibitor α-hydroxyglutarate (2HG). 2HG is selectively and synthetically lethal to TET2-deficient HSCs reliant for their survival on minimal residual dioxygenase activity supplied by less abundant TET1 and TET3. This observation inspired the idea of generating TET inhibitors as drugs selective for TET2 mutant (TET2MT) leukemia cells. Based on the structure of 2HG, investigator generated a more potent TETi76, and showed that this drug is indeed synthetically lethal to TET2MT and TET2 proficient cells. In search for alternative agents with suitable activity, investigator next performed a high throughput drug screen using an in vitro DNA dioxygenase assay. Among several hits, eltrombopag (EPAG) was unique, as it is already used in clinical practice as a thrombopoietin receptor (TPOR) agonist. Investigator showed that this agent inhibited growth of TET2MT cells in murine TET2MT models independent of its TPOR activity, and have determined its binding site and mode of action on TET dioxygenases.1 Since EPAG is an FDA approved drug with known toxicities and good tolerability, repurposing this agent as a TET inhibitor would greatly shorten the development time and thus rapidly provide a selective and well-tolerated drug for the therapy of patients with TET2MT MDS. Investigators have obtained granular molecular and response data from historical trials of EPAG/5Azacytidine in unselected MDS and aplastic anemia (AA) and were able to retrospectively assert that indeed those with TET2MT disease responded to EPAG therapy, resulting in decreased TET2MT clonal burden.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Established diagnosis of very low-, low-, or intermediate-risk MDS (IPSS-R \< 3.5) and \< 5% myeloblasts or CMML 0 (CMML-0, for cases with \< 2% blasts in PB and \< 5% blasts in bone marrow (BM)z,[14] with any one of the notable cytopenias as defined below:
Adequate organ function, defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Enrolled participants will receive EPAG 50 mg daily, 2h prior to or after meals for 1 cycle
Drug: Eltrombopag (EPAG)
50 mg, 28-day cycles, 3 initial cycles + 12 cycles on extension arm (maximum of 15 cycles)
Also known as: Promacta
Response Rate as assessed by hematologic response
Response rate will be assessed to determine whether treatment with EPAG can induce a hematologic response. The different types of hematologic improvement are Erythroid response (non-transfusion dependent, Erythroid response (transfusion dependent), Platelet response (pretreatment, \> 20 × 109/L), Platelet response (pretreatment, \< 20 × 109/L), Neutrophil response, and Progression or relapse after HI (after reaching maximum dose, and on maximum dose for 12 weeks).
Time frame: At end of treatment (approximately up to 12 weeks)
AML-free survival
AML-free survival will be calculated using the Kaplan-Meier method
Time frame: At end of treatment (approximately up to 12 weeks)
Progression Free Survival
Progression free survival will be calculated using the Kaplan-Meier method
Time frame: At end of treatment (approximately up to 12 weeks)
Change in TET2 mutation burden as measured by variant allele fraction.
Change in mutant TET2 variant allele fraction
Time frame: Baseline, end of cycle 3(28 days per cycle), end of treatment(approximately up to 12 weeks)
Rates of robust response as measured by platelet count
Robust response will be summarized with a frequency and 95% confidence interval.
Time frame: Approximately at 24 weeks post administration of intervention
Rates of robust response as measured by hemoglobin
Robust response will be summarized with a frequency and 95% confidence interval.
Time frame: Approximately at 24 weeks post administration of intervention
Rates of robust response as measured by ANC
Robust response will be summarized with a frequency and 95% confidence interval.
Time frame: Approximately at 24 weeks post administration of intervention
Plan to share: Yes — All IPD that underlie results in publication will be shared as a combined summary. Any individual outcomes published per subject will be de- identified utilizing the subject ID (e.g., dosing, demographics, adverse events, etc.)
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data included in the peer reviewed publication will be publicly available starting 6 months after publication and will be available indefinitely. No raw data will be shared.
Access criteria: A peer-reviewed publication will be made available according to the publishing journal's specifications. CCF personnel will not share study data apart from that which has been published publicly.
Data sharing details ↗ · pubmed.ncbi.nlm.nih.gov
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Jan 2028, 30 months after the start.
Of 227 non-industry phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 116. This study's planned 30 months is below that.
Counting every sponsor, half of 279 studies reached it within 65 months; a quarter within 39 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eltrombopag